Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.

Wattmo C, Wallin ÅK.

Alzheimers Res Ther. 2017 Aug 31;9(1):70. doi: 10.1186/s13195-017-0294-2.

2.

Few serum proteins mediate APOE's association with dementia.

Royall DR, Al-Rubaye S, Bishnoi R, Palmer RF.

PLoS One. 2017 Mar 14;12(3):e0172268. doi: 10.1371/journal.pone.0172268. eCollection 2017.

3.

Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.

Seo EH, Kim SH, Park SH, Kang SH, Choo IH; Alzheimer's Disease Neuroimaging Initiative.

J Korean Med Sci. 2016 Feb;31(2):286-95. doi: 10.3346/jkms.2016.31.2.286. Epub 2016 Jan 13.

4.

APOEε2 is associated with milder clinical and pathological Alzheimer disease.

Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT.

Ann Neurol. 2015 Jun;77(6):917-29. doi: 10.1002/ana.24369.

5.

The potential applications of Apolipoprotein E in personalized medicine.

Villeneuve S, Brisson D, Marchant NL, Gaudet D.

Front Aging Neurosci. 2014 Jul 8;6:154. doi: 10.3389/fnagi.2014.00154. eCollection 2014. Review.

6.

Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction.

Ungar L, Altmann A, Greicius MD.

Brain Imaging Behav. 2014 Jun;8(2):262-73. doi: 10.1007/s11682-013-9272-x. Review.

7.

Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.

Wattmo C, Wallin AK, Minthon L.

Alzheimers Res Ther. 2013 Oct 7;5(5):44. doi: 10.1186/alzrt210. eCollection 2013.

8.

APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease.

Chang YL, Fennema-Notestine C, Holland D, McEvoy LK, Stricker NH, Salmon DP, Dale AM, Bondi MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 May;10(3):336-48. doi: 10.1016/j.jalz.2013.05.1763. Epub 2013 Jul 27.

9.

Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.

Head D, Bugg JM, Goate AM, Fagan AM, Mintun MA, Benzinger T, Holtzman DM, Morris JC.

Arch Neurol. 2012 May;69(5):636-43.

10.

Molecular insights into the pathogenesis of Alzheimer's disease and its relationship to normal aging.

Podtelezhnikov AA, Tanis KQ, Nebozhyn M, Ray WJ, Stone DJ, Loboda AP.

PLoS One. 2011;6(12):e29610. doi: 10.1371/journal.pone.0029610. Epub 2011 Dec 28.

11.

Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease.

Mielke MM, Leoutsakos JM, Tschanz JT, Green RC, Tripodis Y, Corcoran CD, Norton MC, Lyketsos CG.

J Alzheimers Dis. 2011;26(1):127-34. doi: 10.3233/JAD-2011-110086.

12.

Noninvasive brain stimulation in Alzheimer's disease: systematic review and perspectives for the future.

Freitas C, Mondragón-Llorca H, Pascual-Leone A.

Exp Gerontol. 2011 Aug;46(8):611-27. doi: 10.1016/j.exger.2011.04.001. Epub 2011 Apr 14. Review.

13.

Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia.

Reitz C, Mayeux R.

J Alzheimers Dis. 2010;19(1):229-51. doi: 10.3233/JAD-2010-1255. Review.

14.

Trajectories of cognitive decline in Alzheimer's disease.

Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, DeKosky ST, Sweet RA.

Int Psychogeriatr. 2010 Mar;22(2):281-90. doi: 10.1017/S1041610209991001. Epub 2009 Sep 28.

15.

The FAS gene, brain volume, and disease progression in Alzheimer's disease.

Erten-Lyons D, Jacobson A, Kramer P, Grupe A, Kaye J.

Alzheimers Dement. 2010 Mar;6(2):118-24. doi: 10.1016/j.jalz.2009.05.663. Epub 2009 Sep 18.

16.

BDNF variants, premorbid educational attainment, and disease characteristics in Alzheimer's disease: an exploratory study.

Zdanys KF, Kleiman TG, Zhang H, Ozbay F, MacAvoy MG, Gelernter J, van Dyck CH.

J Alzheimers Dis. 2009;17(4):887-98. doi: 10.3233/JAD-2009-1106.

17.

Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.

Small GW, Siddarth P, Burggren AC, Kepe V, Ercoli LM, Miller KJ, Lavretsky H, Thompson PM, Cole GM, Huang SC, Phelps ME, Bookheimer SY, Barrio JR.

Arch Gen Psychiatry. 2009 Jan;66(1):81-7. doi: 10.1001/archgenpsychiatry.2008.516.

18.

APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease.

Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M, Blacker D, Stern Y.

Neurology. 2008 May 6;70(19 Pt 2):1842-9. doi: 10.1212/01.wnl.0000304038.37421.cc. Epub 2008 Apr 9.

Supplemental Content

Support Center